Twist Bioscience (NASDAQ:TWST) Given New $135.00 Price Target at Robert W. Baird

Twist Bioscience (NASDAQ:TWST) had its price target cut by investment analysts at Robert W. Baird from $187.00 to $135.00 in a research report issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird‘s price objective would suggest a potential upside of 18.19% from the stock’s previous close.

A number of other brokerages have also recently commented on TWST. UBS Group initiated coverage on Twist Bioscience in a report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 target price for the company. Leerink Partners increased their price target on Twist Bioscience from $160.00 to $190.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Guggenheim raised their price target on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. BWS Financial restated a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a research report on Friday, September 18th. Finally, Barclays lifted their price objective on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $149.82.

Twist Bioscience Stock Down 6.8%

Shares of NASDAQ TWST opened at $114.22 on Friday. The firm’s 50-day moving average price is $150.57 and its 200-day moving average price is $92.73. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $7.16 billion, a price-to-earnings ratio of -51.45 and a beta of 2.25. Twist Bioscience has a 12-month low of $23.30 and a 12-month high of $219.71.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. The firm’s revenue was up 26.7% compared to the same quarter last year. On average, equities research analysts anticipate that Twist Bioscience will post -2.11 EPS for the current fiscal year.

Insider Activity

In related news, insider Dennis Cho sold 949 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $128,494.60. Following the transaction, the insider owned 62,840 shares of the company’s stock, valued at $8,508,536. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,462 shares of Twist Bioscience stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $156.30, for a total transaction of $384,810.60. Following the sale, the chief financial officer owned 98,114 shares of the company’s stock, valued at $15,335,218.20. The trade was a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 495,279 shares of company stock valued at $80,489,387. Insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the stock. First Trust Advisors LP increased its position in shares of Twist Bioscience by 3.9% during the third quarter. First Trust Advisors LP now owns 198,259 shares of the company’s stock worth $38,312,000 after acquiring an additional 7,380 shares during the period. E Fund Management Hong Kong Co. Ltd. bought a new stake in shares of Twist Bioscience during the third quarter valued at approximately $280,000. Westpac Banking Corp boosted its holdings in shares of Twist Bioscience by 156.7% in the third quarter. Westpac Banking Corp now owns 15,660 shares of the company’s stock valued at $3,026,000 after purchasing an additional 9,560 shares during the period. Private Advisor Group LLC purchased a new stake in shares of Twist Bioscience in the third quarter valued at approximately $523,000. Finally, Ieq Capital LLC boosted its holdings in shares of Twist Bioscience by 7.5% in the third quarter. Ieq Capital LLC now owns 54,948 shares of the company’s stock valued at $10,618,000 after purchasing an additional 3,839 shares during the period.

Twist Bioscience News Summary

These are some of the TWST news items that stood out recently:

• Positive Sentiment: Twist forecast Q1 fiscal 2027 revenue of $130 million–$132 million, above the $126.3 million consensus estimate. It also reported $59.1 million in fiscal 2026 AI drug-discovery revenue. The Motley Fool analysis
• Neutral Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million is only modestly above the $549 million consensus, which may not have been enough to satisfy investor expectations. Seeking Alpha report on guidance
• Negative Sentiment: Despite the quarterly beats, coverage characterized the forward outlook as underwhelming and flagged ongoing cost and profitability concerns. Twist remains loss-making, and this cautious outlook appears to be weighing on the stock. Investor’s Business Daily earnings coverage

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.